EXHIBIT 99.1

NEOSE ANNOUNCES PRICING OF $28,000,000 MILLION OFFERING OF COMMON STOCK

Horsham, PA, February 18, 2005 - Neose Technologies, Inc. (Nasdaq NM: NTEC)
today announced the pricing of its public offering of 7,000,000 shares of common
stock at a price of $4.00 per share under an existing shelf registration
statement. The gross proceeds of the offering will be $28,000,000 million. Neose
has granted the underwriters a 30-day option to purchase up to 1,050,000
additional shares of its common stock at the same price per share to cover
over-allotments, if any.

UBS Investment Bank is acting as the sole book-running manager in this offering.
J.P. Morgan Securities, Inc. and Jefferies & Company, Inc. are acting as
co-managers.

This press release shall not constitute an offer to sell or the solicitation of
an offer to buy any of the securities described herein, nor shall there be any
sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction. A final prospectus
relating to these securities will be filed with the Securities and Exchange
Commission. The offering of the shares of common stock may be made only by means
of the prospectus supplement and related prospectus, copies of which will be
available from UBS Investment Bank, Prospectus Department, 299 Park Avenue, New
York, NY 10171.

ABOUT NEOSE

Neose is a biopharmaceutical company using its proprietary enzymatic
technologies to develop improved drugs, focusing primarily on therapeutic
proteins. Neose uses its GlycoAdvance(TM) and GlycoPEGylation(TM) technologies
to develop improved versions of drugs with proven safety and efficacy. Neose
intends to apply its technologies to products it is developing on its own and to
products it co-develops and co-owns with others. It also expects to make its
technologies available, through strategic partnerships, to improve the products
of other parties. Neose's first two proprietary candidates are GlycoPEG-EPO
(NE-180), a long-acting version of erythropoietin, and GlycoPEG-GCSF, a
long-acting version of granulocyte colony stimulating factor (G-CSF). It is
expected that an investigational new drug application (IND) for NE-180 will be
submitted to the U.S. Food and Drug Administration (FDA) during the second
quarter of 2005. In addition, it is expected that the equivalent of an IND will
be submitted in an EU country by the end of 2005 for GlycoPEG-GCSF.

CONTACTS:

Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President
and Chief Financial Officer



Barbara Krauter
Manager, Investor Relations
(215) 315-9000
E-mail: info@neose.com

For more information, please visit www.neose.com.

Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act
of 1995: Statements in this press release regarding our business that are not
historical facts are "forward-looking statements" that involve risks and
uncertainties. For a discussion of these risks and uncertainties, any of which
could cause our actual results to differ from those contained in the
forward-looking statement, see the section of Neose's Annual Report on Form 10-K
for the year ended December 31, 2003, entitled "Factors Affecting the Company's
Prospects" and discussions of potential risks and uncertainties in Neose's
subsequent filings with the SEC.